Overview

Study Of 323U66 SR In Major Depressive Disorder

Status:
Completed
Trial end date:
2007-05-28
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Bupropion